(MedPage Today) — The FDA said that “manipulated” data supported the approval of avacopan (Tavneos) for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, and the agency is proposing to withdraw the drug’s marketing approval…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
